fundamental [1:2 hours. 1 Dilution Remove the volume of diluent equal to the total required volume of reconstituted siltuximab solution from a 250-mL bag of 5% dextrose injection. 1 Then slowly add total required volume of reconstituted siltuximab solution to the diluent in a diethylhexyl phthalate (DEHP)-plasticized PVC or non-PVC (polyolefin) infusion bag. 1 Mix the diluted solution by gentle inversion. 1 Complete infusion within 4 hours of the dilution of the reconstituted solution (including infusion time). 1 Rate of Administration Administer by IV infusion over 60 minutes. 1 Dosage Adults MCD IV 11 mg/kg every 3 weeks. 1 Continue therapy until treatment failure. 1 Therapy Interruption for Toxicity Hematologic Toxicity Manufacturer recommends considering delaying administration of the first dose of siltuximab in patients with an ANC] FEATURED: CAR-T Cell Therapy Overview Mechanism of Action KTE-C19 Studies KTE-C19 Cancer Targets Adverse Events Manufacturing Drug Status Rx Availability Prescription only C Pregnancy Category Risk cannot be ruled out N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Drug Class Interleukin inhibitors Related Drugs Multicentric Castleman s Disease Sylvant , More... Siltuximab Rating No Reviews - Be the first! No Reviews - Be the first! Not Rated - Be the first! the reality
effective Siltuximab realise
EmoticonEmoticon